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A B S T R A C T
Mutations at the TP53 gene are readily detected (approximately 50–75%) in pancreatic ductal
adenocarcinoma (PDAC) patients. TP53 was previously thought to be a difficult target as it is
often mutated, deleted or inactivated on both chromosomes in certain cancers. In the following
study, the effects of restoration of wild-type (WT) TP53 activity on the sensitivities of MIA-PaCa-2
pancreatic cancer cells to the MDM2 inhibitor nutlin-3a in combination with chemotherapy, tar-
geted therapy, as well as, nutraceuticals were examined. Upon introduction of the WT-TP53
gene into MIA-PaCa-2cells, which contain a TP53 gain of function (GOF) mutation, the sen-
sitivity to the MDM2 inhibitor increased. However, effects of nutlin-3a were also observed in
MIA-PaCa-2cells lacking WT-TP53, as upon co-treatment with nutlin-3a, the sensitivity to certain
inhibitors, chemotherapeutic drugs and nutraceuticals increased. Interestingly, co-treatment with
nutlin-3a and certain chemotherapeutic drug such as irinotecan and oxaliplatin resulted in antag-
onistic effects in cells both lacking and containing WT-TP53 activity. These studies indicate the
sensitizing abilities that WT-TP53 activity can have in PDAC cells which normally lack WT-
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TP53, as well as, the effects that the MDM2 inhibitor nutlin-3a can have in both cells containing
and lacking WT-TP53 to various therapeutic agents.
1. Introduction
1.1. Pancreatic cancer: a devastating cancer with few effective therapeutic options
The most common treatment for pancreatic cancer is surgery. Chemotherapy is also a treatment option which has limited success.
Pancreatic cancer is among the top ten most common cancers in the western world. Pancreatic cancer has the highest mortality of any
cancer. It is predicted that pancreatic cancer will soon become the second most frequent cause of cancer deaths. The survival rate is
less than a year with 5-year survival of only 5–10% (Muniraj et al., 2013; Siegel et al., 2013). Unfortunately, the survival rate has not
improved significantly over the past 40 years. Most pancreatic cancers consist of pancreatic ductal adenocarcinoma (PDAC). Clearly
more effective approaches to treat PDAC patients are important to improve cancer care.
The development of PDAC is complex and includes both environmental, as well as, genetic risk factors (Klein, 2012). We have re-
cently summarized the risk and genetic factors associated with development of pancreatic cancer (Abrams et al., 2018, 2019; Candido
et al., 2018). Some of the risk factors for PDAC development in the USA are race and gender based, as well as, diabetes and obesity. In
addition, there are various environmental factors which may contribute to PDAC including: cigarette smoking, alcohol consumption,
and low physical activity (Iodice et al., 2008; Arslan et al., 2010; Jiao et al., 2010; Michaud et al., 2010; Lucenteforte et al., 2012;
Bosetti et al., 2014).
1.2. Existing therapies for PDAC
Removal of the diseased pancreas is a common therapy for PDAC patients (Kommalapati et al., 2018). Combining surgical resec-
tion and chemotherapy is also performed but is only minimally effective. A key problem in PDAC therapy is that by the time PDAC
has been diagnosed, it has already metastasized, often making treatment very difficult if not impossible (Kommalapati et al., 2018;
Ruarus et al., 2018; Skelton et al., 2018).
FOLFIRINOX is a chemotherapeutic regimen which was conceived in the early 2010's. It yields somewhat better results (4 months
longer survival) than standard gemcitabine therapy (Conroy et al., 2011, 2013; Faris et al., 2013; Thota et al., 2014). The FOLFIRI-
NOX regime consist of four drugs namely: FOL=folinic acid (leucovorin), a vitamin B derivative that reduces the side effects of,
F=fluorouracil, a pyrimidine analog that becomes introduced into DNA and blocks replication, IRIN=irinotecan (Camptosar), a
topoisomerase inhibitor, that inhibits DNA uncoiling and duplication and OX=oxaliplatin (Eloxatin), a platinum-based antineoplastic
agent, which inhibits DNA repair and replication.
Combining gemcitabine (Gemzar) and protein-bound paclitaxel (nab-paclitaxel, Abraxane) has been evaluated in the treatment
of certain patients with advanced pancreatic cancer (Von Hoff et al., 2011). This therapy was approved by the US Food and Drug
Administration since 2013. The combination of gemcitabine and nab-paclitaxel may have less side effects than FOLFIRINOX therapy.
1.3. Pancreatic cancer genetics: some common oncogenes/tumor suppressor genes and some novel culprits
It turns out that PDACs have mutations at certain oncogene/tumor suppressor genes which are frequently mutated in human can-
cer including: KRAS, TP53, CDKN2A, and SMAD4 (Rasheed et al., 2015; Klein, 2012, 2013). At least 90% of PDACs contain activating
mutations in KRAS. The constitutively-activated KRAS oncoprotein interacts and often mobilizes many downstream signaling path-
ways (e.g., PI3K/Akt/mTOR and Raf/MEK/ERK) leading to: proliferation in absence of regulatory growth factors, cell cycle progres-
sion, prevention of apoptosis, senescence and chemotherapeutic drug resistance.
The genetic status of: KRAS, TP53, isocitrate dehydrogenase 1 (IDH1), NRAS and BRAF, as well as, the expression of SMAD4 and
CDKN2A/p16 were examined in fifteen long-term PDAC survivors. Long-term PDAC survivors are defined as patients who have sur-
vived for longer than 55 months as most PDAC cancer patients succumb less than 20 months after tumor resection. Lack of mutation
at KRAS and TP53 and expression of SMAD4 were associated with a 2-fold longer survival than patients who had mutations at or lost
expression of these genes (Masetti et al., 2018).
Many of the genes associated with familiar PDAC are also implicated in sporadic PDAC. These include: ATM, BRCA2, DPC4, PALB2,
PIK3CA, SMAD and others (Blackford et al., 2009; Roberts et al., 2012, 2016; Klein, 2013; Wolpin et al., 2014; Norris et al., 2015).
Network analysis (Zhang et al., 2017) is also being used to identify genes which may be involved in PDAC. Novel genes implicated
in tumor diversity and evolution are being identified by restriction-site associated DNA sequencing (RADseq) (Perry et al., 2017).
Patient-derived xenografts made from human PDAC tumor specimens are also being created to identify additional genes that are aber-
rantly expressed in PDAC. These animal models may also allow the screening of novel therapeutics useful in treating PDAC (Jung et
al., 2016).
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1.4. Roles of TP53 in PDAC
The transcription factor TP53 controls the expression of many genes and microRNAs (miRs). These genes and miRs (e.g., p21⁠Cip−1,
NOXA, PUMA, miR-34a) and many others are involved in the regulation of cell cycle progression, apoptosis, cellular senescence and
other critical biological processes important in normal growth, as well as, cancer progression and drug resistance (Chen et al., 1996;
Ko and Prives, 1996; Olivier et al., 2002). TP53 is one of the most frequently mutated oncogenes in human cancers.
Recently, the NOP14 nucleolar protein (NOP14) was detected at higher levels in PDAC tumors and metastatic tissue samples than
in normal controls. This increased expression of NOP14 resulted in enhanced cell motility. In contrast, suppression of NOP14 de-
creased invasiveness. Intriguingly, mutant TP53 was demonstrated to be a target of NOP14. NOP14 increased mutant TP53 mRNA
stability. NOP14 and mutant TP53 had effects on cell cycle progression as they suppressed p21⁠Cip−1 expression at both the transcrip-
tional and post-transcriptional levels. This may have resulted from the induction of the miR-17–5p. Thus, certain genes and proteins
may interact with mutant TP53 to alter cell cycle progression, as well as, metastasis (Du et al., 2017).
1.5. Gain of function (GOF) mutant TP53 proteins-devilish mutations in disguise
Many TP53 mutant proteins have a single amino acid change. They are often missense mutations. These mutations can result in
changing the levels of the TP53 proteins, by increasing the protein levels due to altered degradation of the normally labile TP53
protein. Certain mutant TP53 proteins have GOF activity. That is, they have additional “functions or characteristics” which WT-TP53
lacks. These mutations can occur at the TP53 gene in critical residues that result in altered transcriptional programs for TP53 and
some may also inhibit the normal functions of TP53.
GOF mutations may have more effects than deletions of the TP53 gene in pancreatic cancer. GOF mutations may affect genome
stability and responses to chemotherapeutic drugs such as altering induction of cellular senescence. The R248W, R273H and R175H
GOF TP53 mutations are predicted to be present in approximately 15% of TP53 mutations, thus they may occur in 8% of all human
cancers as TP53 is predicted to be mutated in 50% of human cancers (Liu et al., 2010). The MIA-PaCa-2cell line contains the R248W
TP53 mutation (Morton et al., 2010). TP53 GOF mutations such as R248W may alter the ability of TP53 to bind DNA and transcribe
certain genes. Also, these mutations affect the ability of TP53 to interact with other transcription factors (TP63, TP73) and anti-apop-
totic proteins such as BCLXL and may lead to the deregulation of apoptosis. The R248W and R282W TP53 mutations are associated
with shorter patient survival. These TP53 mutations have been referred to as “mortality mutations” (Xu et al., 2014). Some other
studies have indicated that TP53 GOF knock-in mice do not show altered survival in comparison to mice lacking TP53 (p53−/−) but
the mice containing the TP53 GOF knock-in genes exhibit a broader tumor spectrum (Hanel et al., 2013).
Multiple effects have been demonstrated for the R248W TP53 mutant protein. In knock-in mice, it was demonstrated that the
R248W TP53 mutant protein could interact with the MRE11 nuclease and prevent the binding of the MRE11-Rad50-NBS1 (MRN)
complex to double strand DNA breaks (DSB). This prevented ataxia-telangiesctasia mutated (ATM) activation, an important molecule
involved in DNA repair (Song et al., 2007). ATM is also mutated in certain PDAC patients (Roberts et al., 2012).
The R248W-TP53 mutant protein increases the expression of the growth–regulated oncogene 1 (GRO1 a.k.a. CXCL1, a small cy-
tokine, growth promoting protein) and decreases the expression of the inhibitor of DNA Binding 2 (ID2, a transcriptional regulator)
which are important in growth regulation of cells containing the mutant TP53 gene (Brosh and Rotter, 2009). CXCL1 may play key
roles in the pancreatic tumor microenvironment and tumor development. CXCL1 is a potent chemoattractant for myeloid cells. The
necrosome and CXCL1 have been shown recently to be important in PDAC (Seifert et al., 2016), however, the roles of mutant (s)
and WT TP53 are not known. The necrosome induces CXCL1. Necroptosis (programmed necrosis) is another form of programmed cell
death and is important in PDAC.
Various missense TP53 proteins regulate (induce or repress) the expression of other genes including: FAS (a.k.a., CD95), ID2,
multi-drug resistance-1 (MDR1, ABCB1), c-Myc (MYC) and NF-kappaB2 (NFKB2) and many others (Brosh and Rotter, 2009). The spec-
trum of genes regulated by mutant TP53 missense proteins is often different than the proteins regulated by WT-TP53. Certain TP53
mutant proteins can form heterotetramers with WT-TP53. The C-terminal basic domain of the WT-TP53 protein has been shown to
inhibit the activity of mutant R248W and other TP53 mutant proteins (Yan and Chen, 2010; Zhang et al., 2016a).
Previously, we and others have examined the roles of TP53 in the sensitivity of hematopoietic, prostate and pancreatic cells and
other cancer types to chemotherapeutic drugs and, in some cases, radiation (Lehmann et al., 2007’ McCubrey et al., 2008; Chappell
et al., 2012; Abrams et al., 2017; Steelman et al., 2017; Abrams et al., 2018; Abrams et al., 2019). We observed that introduction
of dominant negative (DN)-TP53 into FL5.12 hematopoietic cells increased their chemoresistance (McCubrey et al., 2008; Abrams
et al., 2017; Steelman et al., 2017). The biological effects of addition of WT-TP53 or DN-TP53 to cells which either lack or have
WT-TP53 have been examined in prostate cancer cells (Lehmann et al., 2007; Chappell et al., 2012). Introduction of WT-TP53 into
prostate cancer, DU145cells which expressed mutant TP53, resulted in increased chemosensitivity and radiosensitivity (Lehmann et
al., 2007; Chappell et al., 2012). Introduction of WT-TP53 also increased the induction of cellular senescence after radiation treat-
ment and sensitivity to the MDM2 inhibitor nutlin-3A when the cells were treated with the TP53-inducer doxorubicin (Chappell et
al., 2012). Introduction of WT-TP53 increased TP53-mediated luciferase activity in prostate cancer cells which had defective TP53,
while introduction of DN-TP53 suppressed TP53 luciferase activity in LNCaP cells with WT-TP53 (Lehmann et al., 2007; Chappell et
al., 2012). In addition, introduction of WT-TP53 suppressed the ability of prostate cells with mutant TP53 (DU145 and PC3) to form
colonies in soft agar (Chappell et al., 2012), while introduction of WT-TP53 increased the ability of prostate cancer cells with WT-
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TP53 activity to form colonies in soft agar (Chappell et al., 2012). The ability of cells to form colonies in soft agar has been associ-
ated with malignant progression (Shin et al., 1975). WT-TP53 activity was critical in controlling the induction of pre-mature cellular
senescence after radiation treatment of prostate cancer cells (Lehmann et al., 2007).
Introduction of WT-TP53 was observed to increase the sensitivity of certain PDAC cells to certain chemotherapeutic drugs, signal
transduction inhibitors and nutraceuticals (Abrams et al., 2018, 2019). Reprogramming TP53 is a potent target for pancreatic cancer
therapy (Saghatelian et al., 2017). Thus, TP53 is a key regulatory molecule in processes involved in malignant progression, chemosen-
sitivity and radiosensitivity.
1.6. TP53 roles in PDAC metastasis
Dense fibrotic stroma is associated with PDAC and can contribute to tumor growth, metastasis and lead to drug resistance. Qui-
escent pancreatic stellate cells (PSCs) often become activated during PDAC growth which can lead to increased growth factor signal-
ing. This can result in extracellular matrix deposition and fibrosis. The E3 ubiquitin-protein ligase mouse double minute 2 homolog
(MDM2) inhibitor nutlin-3a can activate TP53 and this then regulates PSC activation and modulates PDAC fibrosis. This results in
transcriptional changes which lead to PSC quiescence (Saison-Ridinger et al., 2017).
TP53 mutations have been frequently detected during the transition from benign pancreatic intra-epithelial neoplasia to the highly
aggressive, invasive and metastatic PDAC. These mutations can play critical roles in PDAC progression and may result in loss of
TP53's anti-proliferative effects. However, some missense mutations result in GOF mutations. Platelet-derived growth factor receptor
b (PDGFRb) was demonstrated to be involved in the invasiveness of PDAC cells. The p73/NF Y complex was suppressed in these
cells which in turn inhibited invasion in vivo. PDGFRb expression in pancreatic, colon and ovarian cancer patients was associated with
poor disease-free survival (Weissmueller et al., 2014).
1.7. Increasing TP53 activity by targeting with the MDM2 inhibitor Nutlin-3a
The level of the labile TP53 protein is controlled, in part, by MDM2. Nutlin-3a is an example of a MDM2 inhibitor which has been
characterized in multiple cancer types (Vassilev et al., 2004). Various small molecule MDM2 inhibitors are under investigation and
some are being evaluated in clinical cancer trials (Vu and Vassilev, 2011; Khoo et al., 2014). Recently, we have summarized MDM2
and related MDM4 proteins and their inhibitors and some of the mechanisms of resistance to these inhibitors (McCubrey et al., 2017).
The potential for inhibitors such as nutlin-3a and other MDM2 inhibitors either alone or in combination with chemotherapeutic drugs
to suppress the growth of tumor cells containing WT-TP53 or mutant TP53 has been discussed (Ambrosini et al., 2007; Zhang et al.,
2011; Conradt et al., 2013).
The fruits Garcinia mangostana L and Garcinia hanburyi contain prenylated xanthones alpha-mangostin and gambogic acid respec-
tively. These compounds have some natural MDM2 inhibitory activity (Leão et al., 2013). Thus, MDM2 represents a target which has
been selected by evolution of nutraceuticals.
1.8. Reactivating mutant TP53
An alternative approach of TP53-directed therapeutics is to reactivate TP53 activity in TP53-mutant cancers. APR-246, [(a.k.a.,
PRIMA-1, PRIMA-1 (MET)] is a small molecule drug that binds critical cysteine residues in the core binding domain of mutant TP53
and results in reactivation of TP53 activity (Bykov et al., 2002; Zache et al., 2008; Zandi et al., 2011). These mutant TP53 “reactiva-
tors” may function as chaperones and bind mutant TP53 and related TP63 and TP73 proteins. These TP53 “reactivators” stabilize the
proteins and maintain the correctly folded protein conformation.
PRIMA-1 (MET) (APR-246) has been evaluated in some clinical trials with hematopoietic prostate and ovarian cancers (Lehmann
et al., 2012). PRIMA-1 (MET) and other MDM2 inhibitors have been examined on cancer stem cells (Zhang et al., 2016b). PRIMA-1
(MET) enhanced the effects of the poly ADP ribose polymerase (PARP) inhibitor AZD2281 (olaparib) in non-small cell lung cancer
cells (Deben et al., 2016). PRIMA-1 (MET) also increased the sensitivity of V600E/K BRAF mutant melanomas to the BRAF inhibitor
vermurafenib (Krayem et al., 2016). PRIMA-1 (MET) (APR-246) will suppress cisplatin- and doxorubicin-resistance in ovarian cancer
cells (Mohell et al., 2015).
1.9. Targeting signal transduction pathways induced by chemotherapy
Chemotherapy can induce TP53 and NF-κB and other molecules such as Raf/MEK/ERK and PI3K/PTEN/AKT/mTOR and other
pathways which are involved in the resistance to multiple therapeutic approaches (Abrams et al., 2017; Steelman et al., 2017). Many
signaling pathways, nutraceuticals and natural products interact with NF-κB and TP53 and other pathways which are involved with
drug resistance (McCubrey et al., 2017, 2018). In addition, the TP53 and NF-κB pathways may be induced by nutraceuticals.
As stated previously, TP53 is frequently mutated in PDAC. Multiple signaling pathways may be affected by mutant TP53 (Solomon
et al., 2012; Abrams et al., 2017; Steelman et al., 2017; McCubrey et al., 2018). Mutations in TP53 have pleiotropic effects, which can
contribute to cancer progression.
In the following studies, we have investigated the effects of the MDM2 inhibitor nutlin-3a on a pancreatic cell line, MIA-PaCa-2
which has a GOF TP53 mutation and in a derivative cell line which has an introduced WT-TP53 gene to determine the effects of var
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ious chemotherapeutic drugs, signal transduction inhibitors, natural products on the sensitivity to nutlin-3a. We observed that in some
cases the cells lacking WT-TP53 were sensitive to the nutlin-3a when combined with chemotherapeutic drugs suggesting that the
MDM2 inhibitor may have effects on certain PDAC cell with TP53 GOF mutations. An overview of the effects of nutlin-3a, chemother-
apeutic drugs, signal transduction inhibitors on TP53, miR-34a and downstream signal pathways important in PDAC as well as the
progression of other cancers is presented in Fig. 1.
2. Materials and methods
2.1. Cell lines and tissue culture
The MIA-PaCa-2 PDAC (ATCC⁠® CRM-CRL-1420™) carcinoma cell line was derived from a 65-year old Caucasian male (Deer et al.,
2010). MIA-PaCa-2cells have the R248W TP53 GOF mutation. The R248W TP53 mutation present in MIA-PaCa-2cells is a missense
point mutation in the central DNA binding domain which abrogates its DNA contact (Liu et al., 2010). This TP53 mutation results in
a TP53 protein that is unable to bind to all TP53 target sequences in TP53-responsive genes and results in loss of its tumor suppressor
properties (Brosh and Rotter, 2009; Solomon et al., 2012). In addition, the TP53 GOF mutation may result in the transcription of
genes which are not normally targets of WT-TP53. MIA-PaCa-2cells also have an activating mutation at KRAS (G12C) and they have
elevated PI3K/AKT pathway activity. MIA-PaCa-2cells were obtained from the ATCC (Rockville, MD, USA). MIA-PaCa-2cells were
infected with the pLXSN empty viral vector (Miller and Rosman, 1989) or a retroviral vector encoding WT-TP53 (Eliyahu et al., 1989)
as described (Abrams et al., 2018) and stable pools isolated in the presence of medium containing 2mg/ml geneticin (Sigma-Aldrich,
Saint Louis, MO, USA).
Cells were cultured in medium containing 5% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA) as described in
(Abrams et al., 2017, 2018, 2019; Steelman et al., 2017; Candido et al., 2018). Tissue culture medium (Dulbecco's modified Ea-
gles medium, DMEM), antibiotics containing L-glutamine and trypsin were obtained from Invitrogen (Carlsbad, CA, USA). Nutraceu-
ticals, chemotherapeutic drugs, and signal transduction inhibitors were purchased from either Selleckchem (Houston, TX USA) or
Sigma-Aldrich.
2.2. Methylthiazol tetrazolium assays
Methylthiazol tetrazolium (MTT) assays were performed to ascertain the sensitivity of the pancreatic cancer cells containing and
lacking an introduced WT-TP53 gene, or a control empty retroviral pLXSN control vector to chemotherapeutic drugs, signal trans-
duction inhibitors and nutraceuticals as described (Abrams et al., 2018, 2019). To test the hypotheses that the various IC⁠50s in the
pancreatic cancer cells containing or lacking WT-TP53 that were treated with chemotherapeutic drugs, signal transduction inhibitors,
nutraceuticals and nutlin-3a were statistically different, student's T tests were performed by Graph Pad Prism (QuickCals) statistical
analysis.
Fig. 1. Overview of Effects of Nutlin-3 on TP53 and miR-34a Expression. The effects of various drugs on the TP53 and miR-34a are indicated. The sites of interac-
tion of various signal transduction pathway inhibitors are indicated. The effects of miR-34a activation on important pathways involved in cancer progression and other
physiological processes are indicated.
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3. Results
3.1. Introduction of WT-TP53 alters the sensitivity of MIA-PaCa-2 cells to various chemotherapeutic drugs and signal transduction inhibitors
MIA-PaCa-2 cells were infected with the empty retroviral vector pLXSN as a control for infection with the retrovirus encod-
ing WT-TP53. The experiments in this manuscript were performed with adherent (Adh.) cells. It is important to state whether the
MIA-PaCa-2 cells are adherent or spheroid as they will also grow non-adherently as spheroids. MTT analyses were used to determine
the effects of TP53 on the chemosensitivity of MIA-PaCa-2 + WT-TP53 (Adh.) cells to the MDM2 inhibitor. The IC⁠50 for nutlin-3a in
MIA-PaCa-2 + WT-TP53 (Adh.) cells was approximately 10,000 nM (Fig. 2, Panel A). In contrast, an IC⁠50 for nutlin-3a was not ob-
tained in MIA-PaCa-2 + pLXSN (Adh.) cells with up to 10,000 nM documenting the resistance of cells lacking WT-TP53 to this MDM2
inhibitor. The IC⁠50s for gemcitabine were also examined. In MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) the
IC⁠50s for gemcitabine were 6nM and 0.4nM respectively, approximately a 15-fold increase in sensitivity in cells containing WT-TP53.
(Fig. 2, Panel B). These results demonstrate the effects that WT-TP53 can have on the sensitivity of the cells to various drugs. The
effects of introduction of WT-TP53 on the sensitivity to various chemotherapeutic and nutraceuticals are summarized in Table 1.
3.2. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals
The effects of combining gemcitabine with a constant dose of 500 nM nutlin-3a were examined in MIA-PaCa-2 + pLXSN and
MIA-PaCa-2 + WT-TP53 (Fig. 2, Panels C & D). The IC⁠50 for nutlin-3a in MIA-PaCa-2 + pLXSN (Adh.) was approximately 6 nM (Fig.
2, Panel C). Inclusion of a constant sub-IC⁠50 dose of 500nM nutlin-3a reduced the gemcitabine IC⁠50 1.5-fold to 4nM. The IC⁠50 for gem-
citabine in MIA-PaCa-2 + WT-TP53 (Adh.) cells was approximately 0.6 nM (Fig. 1, Panel D), Addition of 500nM nutlin-3a reduced
the IC⁠50 2-fold to 0.3nM. The effects of a sub-IC⁠50 dose of nutlin-3a in the presence and absence of WT-TP3 on the IC⁠50s of various
chemotherapeutic drugs and nutraceuticals are summarized in Table 2.
Fig. 2. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Nutlin-3a and Gemcitabine. MIA-PaCa-2 + pLXSN (red squares), and
MIA-PaCa-2 + WT-TP53 (blue triangles) cells were titrated with different concentrations of Panel: A) nutlin-3a and B) gemcitabine for 4 days before MTT analysis was
performed. Arrows on the X-axis indicate where the IC⁠50s can be estimated. In Panel B, the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + pLXSN (Adh.)
and MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with gemcitabine and is extremely statistically significant. The experiments in panels A and B were performed on the
same days. These experiments were repeated 4 times and similar results were obtained. Adh. = adherent cells. In Panel C) MIA-PaCa-2 + pLXSN (Adh.) and in Panel
D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of gemcitabine (solid red squares) and a constant dose of 500 nM nutlin-3a (solid
blue triangles) and then MTT analysis was performed after 4 days. In Panel C, the two-tailed P value equals 0.0058 between MIA-PaCa-2 + pLXSN (Adh.) cells treated
with gemcitabine and nutlin-3a and is extremely statistically significant. In Panel D, the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.)
cells treated with gemcitabine and nutlin-3a and is considered to be extremely statistically significant. The experiments in Panels C and D were performed on the same
days. These experiments were repeated 4 times and similar results were observed. (For interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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Table 1
Effects of WT-TP53 on sensitivity to chemotherapeutic drugs and nutraceuticals (IC50 analysis)⁠a.
Presence of WT-TP53→ - WT-TP53 + WT-TP53 Fold Change with introduction of WT-TP53
Drug/Nutraceutical↓
Gemcitabine 6nM 0.4nM 15 X↓
Cisplatin 23,000nM 2,000nM 11.5 X↓
Irinotecan 4,000nM 2,000nM 2 X↓
Oxaliplatin 400nM 400nM –
Mitoxantrone 8nM 5nM 1.6 X↓
BCL2 Inh. (ABT737) 2,000nM 2,000nM –
Berberine 1800nM 700nM 2.6 X↓
Resveratrol 30,000nM 100,000nM 3.3 X↑
Curcumin 30,000nM 20,000nM 1.5 X↓
Garcinia Cambogia 100,000ng/ml 100,000ng/ml –
a IC⁠50 and statistical analyses were determined as described (Abrams et al., 2018, 2019; Candido et al., 2018). Statistical analysis is described in materials and
methods and results section. All IC⁠50 values are presented in nM.
Table 2
Effects of Nutlin-3a on sensitivity to chemotherapeutic drugs in the absence and presence of WT-TP53 (IC⁠50 analysis)⁠a.
Presence of WT-TP53→ – – – + + +
Drug/Nutraceutical↓ Presence of 500nM Nutlin-3a Fold Change Presence of 500nM Nutlin-3a Fold Change
– + – +
Gemcitabine 6nM 4nM 1.5 X↓ 0.6nM 0.3nM 2 X↓
Cisplatin 23,000nM 500nM 46 X↓ 2,000nM 500nM 4 X↓
Irinotecan 4,000nM 12,000nM 3 X↑ 2,000nM 10,000nM 5 X↑
Oxaliplatin 400nM 1,300nM 3.3 X↑ 400nM 1,300nM 3.3 X↑
Mitoxantrone 8nM 2nM 4 X ↓ 5nM 2nM 2.5 X↓
BCL2 Inh. (ABT-737) 2,000nM 60nM 35 X↓ 2,000nM 100nM 10 X↓
Berberine 1,800nM 700nM 2.6 X↓ 700nM 400nM 1.8 X↓
Resveratrol 30,000nM 1,500nM 20 X↓ 100,000nM 13,000nM 7.7 X↓
Curcumin 30,000nM 20,000nM 1.5 X↓ 20,000nM 5,000nM 4 X↓
Garcinia Cambogia 100,000ng/ml 12,000ng/ml 8.3 X↓ 100,000ng/ml 6,000ng/ml 16.7 X↓
a IC⁠50 and statistical analyses were determined as described (Abrams et al., 2018, 2019; Candido et al., 2018). Statistical analysis is described in materials and
methods and results section. All IC⁠50 values are presented in nM.
The IC⁠50 for cisplatin in MIA-PaCa-2 + pLXSN (Adh.) cells was approximately 23 nM (Fig. 3, Panel A), while the IC⁠50 for
MIA-PaCa-2 + WT-TP53 (Adh.) incubated in the presence of cisplatin was approximately 11.5-fold lower (Fig. 3, Panel B). Addition
of 500nM nutlin-3A reduced the IC⁠50 for MIA-PaCa-2 + pLXSN (Adh.) from 23 to 0.5 μM, approximately 46-fold (Panel A). Addition
of 500 nM nutlin-3a, reduced the IC⁠50 for cisplatin 4-fold in MIA-PaCa-2 + WT-TP53 cells from approximately 2 to 0.5 μM (Panel B).
The effects of introduction of WT-TP53 into MIA-PaCa-2 cells on the sensitivity to other drugs frequently used in chemother-
apy were also examined. MIA-PaCa-2 + pLXSN (Adh.) were more resistant to docetaxel (Fig. 3, Panel C) than
MIA-PaCa-2 + WT-TP53 cells (Fig. 3, Panel D). Addition of 500nM nutlin-3a decreased the IC⁠50 for docetaxel approximately 50-fold
in MIA-PaCa-2-TP53cells from 50 to 1nM (Panel D).
The effects of introduction of WT-TP53 into MIA-PaCa-2cells on the sensitivity to irinotecan and oxaliplatin in the presence and
absence of 500nM Nutlin-3A were determined (Fig. 4). MIA-PaCa-2 + WT-TP53 (Adh.) cells were approximately 2-fold more sensi-
tive to irinotecan than MIA-PaCa-2 + pLXSN (Adh.) cells as IC⁠50s of 2 and 4μM were observed respectively (Fig. 4, Panels A & B).
However, when the MIA-PaCa-2 + pLXSN (Adh.) an MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with 500 nM Nutlin-3a and
irinotecan (Panels A & B), interesting results were observed as they became less sensitive to irinotecan and the IC⁠50s increased to
approximately 12 and 10μM, respectively.
When the MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with oxaliplatin, IC⁠50s of ap-
proximately 0.4μM were observed (Fig. 4, Panels C & D). Thus, the presence of WT-TP53 did not appear to alter the chemosen-
sitivity to oxaliplatin. Addition of 500 nM nutlin-3a decreased the sensitivity to oxaliplatin approximately 3.3-fold to 1.3 μM, in
MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells in oxaliplatin indicating that nutlin-3A inhibited the effects of
oxaliplatin.
The effects of introduction of WT-TP53 into MIA-PaCa-2cells on the sensitivity to mitoxantrone and the EGFR/HER2 inhibitor
ARRY 543 were examined in the presence and absence of 500nM nutlin-3a (Fig. 5). MIA-PaCa-2 + pLXSN (Adh.) were more resis-
tant to both mitoxantrone (Panel A) and the ARRY-543 EGFR/HER2 inhibitor (Panel C) than MIA-PaCa-2 + WT-TP53 cells (Panels
B & D). The mitoxantrone IC⁠50 in MIA-PaCa-2 + pLXSN (Adh.) decreased approximately 4-fold, from 8 to 2 nM, when the cells were
treated with 500 nM nutlin-5a. The IC⁠50 for mitoxantrone in MIA-PaCa-2 + WT-TP53 (Adh.) cells was approximately 5 nM (Fig. 5,
Panel B) and decreased approximately 2.5-fold, to 2nM, when the cells were also treated with 500nM nutlin-3a.
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Fig. 3. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Cisplatin and Docetaxel in the Presence and Absence of Nutlin-3a.
In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of cisplatin (solid red squares)
and a constant dose of 500 nM nutlin-3a (solid blue triangle) and then MTT analysis was performed after 4 days. In Panel A, the two-tailed P value is less than 0.0001
between MIA-PaCa-2 + pLXSN (Adh.) cells treated with cisplatin and nutlin-3a and is extremely statistically significant. In Panel B, the two-tailed P value is less than
0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with cisplatin and nutlin-3a and is considered to be extremely statistically significant. The experiments in
Panels A and B were performed on the same days. These experiments were repeated 4 times and similar results were observed. In Panel C) MIA-PaCa-2 + pLXSN (Adh.)
and in Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of docetaxel (solid red squares) and a constant dose of 500 nM nut-
lin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel D, the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53
(Adh.) cells treated with docetaxel and nutlin-3a and is extremely statistically significant. The experiments in Panels C and D were performed on the same days. These
experiments were repeated 4 times and similar results were observed. These experiments were repeated 4 times and similar results were observed. (For interpretation
of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
The IC⁠50 for the EGFR/HER2 inhibitor ARRY-543 was not reached when MIA-PaCa-2 + pLXSN (Adh.) cells were treated with up
to 2,000 nM ARRY-543 (Fig. 5, Panel C). In contrast, when the cells were treated with 500nM nutlin-3a, an IC⁠50 of 800nM was ob-
served. Thus, the addition of nutlin-3a lowered the amount of ARRY-543 required to reach an IC⁠50 dose >2.5 fold.
The IC⁠50 for ARRY-543 in MIA-PaCa-2 + WT-TP53 (Adh.) cells was approximately 2,000 nM (Fig. 5, Panel D). Addition of nut-
lin-3a did not lower the IC⁠50 in MIA-PaCa-2 + WT-TP53 (Adh.) cells significantly but did lower the level of relative growth of the
cells (Fig. 5, Panel D).
The effects of introduction of WT-TP53 on the sensitivity of MIA-PaCa-2cells to the BCL2/BCLXL inhibitor ABT-737 and the Hedge-
hog pathway inhibitor vismodegib were examined (Fig. 6). The IC⁠50 for the ABT-737 BCL2/BCLXL inhibitor in MIA-PaCa-2 + pLXSN
(Adh.) cells was approximately 2,000 nM (Fig. 6, Panel A). Addition of 500nM nutlin-3A sensitized both cell lines to ABT-737. Addi-
tion of a constant dose of 500nM nutlin-3a decreased the IC⁠50 for ABT-737 in MIA-PaCa-2 + pLXSN + pLXSN (Adh) approximately
33-fold, to 60 nM (Fig. 6, Panel A). The IC⁠50 for the ABT-737 in MIA-PaCa-2 + WT-TP53 (Adh.) cells was approximately 2,000 nM
(Fig. 6, Panel B). Addition of 500nM nutlin-3a decreased the IC⁠50 20-fold to approximately 100nM (Fig. 6, Panel B).
The IC⁠50 for the hedgehog pathway inhibitor vismodegib in MIA-PaCa-2 + pLXSN cells was not reached when the cells were
treated with up to 10,000 nM vismodegib (Fig. 6, Panel C). In contrast, when the cells were treated with 500nM nutlin-3a, an IC⁠50
of 5,000 nM was observed which represents at least a 2-fold increase in sensitivity. When MIA-PaCa-2 + WT-TP53 (Adh.) cells were
treated with vismodegib, an IC⁠50 of approximately 10,000nM was observed (Fig. 6, Panel D). Addition of 500nM nutlin-3a increased
the sensitivity of the cells approximately 66.7-fold as an IC⁠50 of 150nM was observed.
Estrogen and 4-hydroxytamoxifen (4HT) can have effects on PDAC cells such as MIA-PaCa-2cells as they express the estrogen
receptor (Guo et al., 2004). With the concentrations of estrogen and 4HT employed in these experiments, neither estrogen nor 4HT
had pronounced effects on MIA-PaCa-2cells which either lacked (Panels A & C) or contained WT-TP53 (Panels B or D) (Fig. 7). How-
ever, the effects of estrogen could be enhanced upon treatment with 500 nM nutlin-3a in MIA-PaCa-2 cells + WT-TP53 (Panel B).
Likewise, the effects of 4HT could be enhanced upon treatment of both cell lines with 500 nM nutlin3a (Panels C & D) as an IC⁠50 of
approximately 100nM was observed.
The effects of the anti-diabetes drug metformin, which induces autophagy, and the anti-malarial drug chloroquine which inhibits
autophagy were examined on cells containing and lacking WT-TP53 in the presence and absence of 500nM nutlin-3a (Fig. 8). Cells
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Fig. 4. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Irinotecan and Oxaliplatin in the Presence and Absence of Nut-
lin-3a. In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of irinotecan (solid
red squares) and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel A, the two-tailed P value is
less than 0.0001 between MIA-PaCa-2 + pLXSN (Adh.) cells treated with irinotecan and nutlin-3a and is extremely statistically significant. In Panel B, the two-tailed
P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with irinotecan and nutlin-3a is extremely statistically significant. The experiments
in Panels A and B were performed on the same days. These experiments were repeated 3 times and similar results were observed. In Panel C) MIA-PaCa-2 + pLXSN
(Adh.) and in Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of oxaliplatin (solid red squares) and a constant dose of 500 nM
nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel C, the two-tailed P value is 0.0027 between MIA-PaCa-2 + pLXSN (Adh.)
cells treated with oxaliplatin and nutlin-3a and is very statistically significant. In Panel D, the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53
(Adh.) cells treated with oxaliplatin and nutlin-3a is less than 0.0001 and is extremely statistically significant. The experiments in Panels C and D were performed on
the same days. These experiments were repeated 4 times and similar results were observed. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
containing WT-TP53 were more sensitive to metformin (Panel B) and chloroquine (Panel D) than cells lacking WT-TP53 (Panels
A & C). Inclusion of 500 nM nutlin-3a sensitized cells containing and lacking WT-TP53 to metformin (Panels A & B) and chloro-
quine (Panels C & D). Addition of 500 nM nutlin-3a to MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with metformin resulted in a
3.3-fold drop in the IC⁠50 from 10,000 nM to 3,000 nM (Panel B). Upon addition of 500 nM nutlin-3a to the chloroquine-treated
MIA-PaCa-2 + WT-TP53 cells resulted in a 7.5-fold decrease in the IC⁠50 from 15 to 2.5μM (Panel D).
The effects of the nutraceuticals berberine and resveratrol were examined on cells containing and lacking WT-TP53 in the pres-
ence and absence of 500nM nutlin-3a (Fig. 9). Cells containing WT-TP53 were more sensitive to berberine (Panel B) than cells lack-
ing WT-TP53 (Panel A) an IC⁠50s of 700 and1,800nM were observed. The IC⁠50 for berberine in MIA-PaCa-2 + pLXSN cells was ap-
proximately 1,800 nM (Fig. 9, Panel A). Upon addition of 500nM nutlin-3a, the IC⁠50 for berberine dropped approximately 2.6-fold,
to 700nM. The IC⁠50 for berberine in MIA-PaCa-2 + WT-TP53 cells was approximately 700 nM (Fig. 9, Panel B). Upon addition of
500nM nutlin-3a, the IC⁠50 dropped approximately 1.8-fold, to 400nM.
When MIA-PaCa-2 + pLXSN (Adh.) cells were treated with resveratrol, an IC⁠50 of approximately 30μM was observed (Fig. 9, Panel
C). When the cells were treated with 500nM nutlin-3a and different doses of resveratrol, the IC⁠50 dropped approximately 20-fold,
to 1.5 μM. When MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with resveratrol, an IC⁠50 of approximately 100μM was observed
(Fig. 9, Panel D). When the same cells were treated with 500nM nutlin-3a, the resveratrol IC⁠50 dropped approximately 7.7-fold, to
13μM. Thus, cells with WT-TP53 were less sensitive to resveratrol than cells containing WT-TP53.
The effects of the nutraceuticals curcumin and garcinia gambogia were examined on cells containing and lacking WT-TP53 in
the presence and absence of 500nM nutlin-3a (Fig. 10). The IC⁠50s for curcumin in MIA-PaCa-2 + pLXSN (Adh.) cells (Fig. 10,
Panel A) and MIA-PaCa-2 + WT-TP53 (Adh.) cells (Fig. 10, Panel B) were approximately 30 and 20 μM, respectively. Treatment of
MIA-PaCa-2 + pLXSN (Adh.) cells (Fig. 10, Panel A) and MIA-PaCa-2 + WT-TP53 (Adh.) cells (Fig. 10, Panel B) with 500nM nut-
lin-3a reduced the IC⁠50s for curcumin approximately 1.5 and 4-fold, to 20 and 5μM, respectively.
When MIA-PaCa-2 + pLXSN (Adh.) cells were treated with garcinia cambogia, an IC⁠50 of approximately 100μg/ml was observed
(Fig. 10, Panel C). When the cells were also treated with 500nM nutlin-3a, the IC⁠50 dropped approximately 8.3-fold–12 μg/ml. When
MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with garcinia cambogia, an IC⁠50 of approximately 100μg/ml was observed (Fig.
10, Panel D). When the same cells were treated with 500nM nutlin-3a, the IC⁠50 dropped approximately 16.7-fold, to 6μg/ml.
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Fig. 5. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Mitoxantrone and the EGFR/HER2 Inhibitor ARRY543 in the Pres-
ence and Absence of Nutlin-3a. In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concen-
trations of mitoxantrone (solid red squares) and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel
A, the two-tailed P value equals 0.0002 between MIA-PaCa-2 + pLXSN (Adh.) cells treated with mitoxantrone and nutlin-3a and is extremely statistically significant.
In Panel B, the two-tailed P value equals 0.0009 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with mitoxantrone and nutlin-3a and is extremely statistically
significant. The experiments in Panels A and B were performed on the same days. These experiments were repeated 3 times and similar results were observed. In Panel
C) MIA-PaCa-2 + pLXSN (Adh.) and in Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of ARRY543 (solid red squares) and a
constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. The experiments in Panels C and D were performed on the
same days. These experiments were repeated 4 times and similar results were observed. (For interpretation of the references to colour in this figure legend, the reader
is referred to the Web version of this article.)
4. Discussion
4.1. Enhancement of effects of chemotherapeutic drugs upon inclusion of the MDM-2 inhibitor Nutlin-3a in MIA-PaCa-2 cells in the presence
and absence of WT-TP53
A goal of our studies was to examine the effects on the MDM-2 inhibitor nutlin-3a on the sensitivity of MIA-PaCa-2cells to
chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals in the presence and absence of WT-TP53. Previously, we
observed that the sensitivity of MIA-PaCa-2cells containing WT-TP53 to 5-fluorouracil and doxorubicin could be enhanced by inclu-
sion of 250nM nutlin-3a (Abrams et al., 2018). In this same study, we also observed that the sensitivities of MIA-PaCa-2cells con-
taining or lacking WT-TP53 to the proteasomal inhibitor MG132 or the PI3K/mTOR inhibitor NVP-BEZ235 were enhanced by the
addition of 250nM nutlin-3a (Abrams et al., 2018). Thus, there are also mechanisms by which nutlin-3a can sensitize cells to certain
signal transduction inhibitors in the absence of WT-TP53. It should be pointed out that the MIA-PaCa-2cells have the R248W TP53
GOF mutation. The effects of nutlin-3a in cells containing TP53 GOF mutation have not been well investigated. In the current study,
we increased the sub-IC⁠50 dose of nutlin-3a to 500nM to determine if the higher concentration of nutlin-3a might induce more effects
on the IC⁠50 of various drugs in cells which either had or lacked WT-TP53. A dose of 500nM nutlin-3a is a sub-IC⁠50 dose for these cells
(Fig. 2, Panel A).
Nutlin-3a treatment will increase TP53 activity in cells with WT-TP53. This can result in the enhancement of miRs including
miR-34a, miR-192, miR-194, and miR-215 (Pichiorri et al., 2010; Rihani et al., 2015). These miRs may regulate key genes involved
in proliferation, apoptosis, drug resistance, epithelial mesenchymal transition (EMT), invasion and metastasis.
In this study, we demonstrated that infection of MIA-PaCa-2cells with a retrovirus encoding WT-TP53 increased their sensitivity
to: gemcitabine, cisplatin, docetaxel, irinotecan, mitoxantrone, vismodegib, chloroquine, and berberine but not resveratrol. In addi-
tion, the addition of 500nM nutlin-3a sensitized the MIA-PaCa-2cells to many chemotherapeutic drugs, signal transduction inhibitor
and natural products in the presence and absence of WT-TP53.
Our studies indicate that introduction of WT-TP53 into PDAC cells which had GOF TP53 mutations resulted in increased sensitiv-
ity to gemcitabine. Mutant TP53 has been shown previously to increase the resistance of PDAC cells to gemcitabine (Fiorini et al.,
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Fig. 6. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to ABT-737 and Vismodegib in the Presence and Absence of Nut-
lin-3a. In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of ABT-737 (solid red
squares) and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel A, the two-tailed P value equals
0.0002 between MIA-PaCa-2 + pLXSN (Adh.) cells treated with irinotecan and nutlin-3a and is extremely statistically significant. In Panel B, the two-tailed P value is
less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with cisplatin and nutlin-3a and is extremely statistically significant. The experiments in Panels
A and B were performed on the same days. These experiments were repeated 3 times and similar results were observed. In Panel C) MIA-PaCa-2 + pLXSN (Adh.) and
in Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of vismodegib (solid red squares) and a constant dose of 500 nM nutlin-3a
(solid blue triangles) and then MTT analysis was performed after 4 days. In Panel D, the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.)
cells treated with vismodegib and nutlin-3a and is extremely statistically significant. The experiments in Panels C and D were performed on the same days. These
experiments were repeated 4 times and similar results were observed. (For interpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
2015). In these studies, gemcitabine was observed to stabilize mutant TP53 proteins in the nuclei. This resulted in expression of Cdk1
and cyclin B1. Treatment with p53-reactivating molecules (CP-31398 and RITA) led to suppression of growth and induction of apop-
tosis in PDAC cells which had either WT or GOF mutant TP53 but not in TP53-null cells. Co-treatment with gemcitabine and the
TP53-reactivating compounds (See Section 4) had synergistic effects which were observed in both WT and mutant TP53-containing
cell lines, but these synergistic effects were not observed in TP53-null cells. Gemcitabine and TP53-reactivator treatment resulted in
phosphorylation of TP53 at Ser15, apoptosis and autophagosome formation. Suppression of autophagy was determined to enhance
the effects of gemcitabine and the CP-31398 treatment. These studies demonstrate the potential for combined therapy of gemcitabine,
TP53-reactivators and autophagy inhibitors in PDAC tumors which are either WT-TP53 or GOF-TP53 mutant, but not in TP53-null
PDAC cells.
Loss of WT-TP53 activity induces the JAK/STAT pathway and gemcitabine-resistance in PDAC mouse models (Wörmann et al.,
2016). This has been associated with PDAC growth and stromal modification. Moreover, loss of TP53 activity and elevation of JAK2/
STAT signaling was associated with poor patient survival.
The effects of a novel MDM2 inhibitor PXN822 and nutlin-3a were examined on murine pancreatic cancer cells that differed in
their presence and absence of WT-TP53 (Conradt et al., 2013). The authors observed that PXN822 treatment could synergistically
enhance the sensitivity to etoposide in a TP53-indepenent fashion. Also, the authors demonstrated that PXN822 could enhance the
sensitivity to doxorubicin. Both etoposide and doxorubicin inhibit topoisomerase II. The authors also demonstrated that MDM2 in-
hibitors delayed the repair of double strand DNA breaks. MDM2 was determines to be involved in the repair of etoposide-induce DNA
double breaks. MDM2 was determined to bind the MRE11–RAD50–Nijmegen breakage syndrome (NBS) 1 DNA repair complex at
NBS1 (Nibrin).
We observed that introduction of WT-TP53 increased the sensitivity of MIA-PaCa-2cells to cisplatin. Cisplatin is a chemotherapeu-
tic drug which is being evaluated as an additional drug in combination with other drugs in PDAC therapy (Borazanci et al., 2018).
The role of WT-TP53 in sensitivity to cisplatin in PDAC cells has not been described well in the scientific literature.
Cisplatin, carboplatin and doxorubicin were demonstrated to increase the cytotoxic effects of nutlin-3a in a panel of mutant
TP53cell lines (Ambrosini et al., 2007). In TP53-mutant peripheral nerve sheath (MPNST) and TP53-null HC116cells, nutlin-3a was
determined to enhance the effects of cisplatin. In the human dedifferentiated liposarcoma LS141 and WT-TP53 HCT116, nutlin-3 in-
duced the down regulation of the E2F transcription factor 1 (E2F1). This downregulation was determined to be proteasome-depen
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Fig. 7. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Estrogen and 4HT in the Presence and Absence of Nutlin-3a. In
Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of estrogen (solid red squares)
and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. The experiments in Panels A and B were per-
formed on the same days. These experiments were repeated 3 times and similar results were observed. In Panel C) MIA-PaCa-2 + pLXSN (Adh.) and in Panel D)
MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of 4HT (solid red squares) and a constant dose of 500 nM nutlin-3a (solid blue trian-
gles) and then MTT analysis was performed after 4 days. The experiments in Panels C and D were performed on the same days. These experiments were repeated 4
times and similar results were observed. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
dent. In contrast, in MPNST and HCT116p53 ⁠−/− cells, nutlin-3a was determined to inhibit the binding of E2F1 to MDM2. This re-
sulted in E2F1 activation in the presence of cisplatin-induced DNA damage. E2F1 normally interacts with the retinoblastoma (RB)
protein to regulate G⁠1/S phase transition. Nutlin-3a was postulated to induce E2F1 in cells lacking WT-TP53 in response to treatment
with certain chemotherapeutic drugs. These studies point to a role for E2F1 in the sensitivity of cells with mutant TP53 to treat-
ment with nutlin-3a and cisplatin. Interestingly, we determined that nutlin-3a could synergize with the proteasome inhibitor MG132
in a TP53-independent fashion previously in both MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) [Abrams et al.,
2018].
Interestingly, combined treatment with nutlin-3a and the topoisomerase-1 inhibitor irinotecan or the platinum-based drug ox-
alplatin did not result in increased cell death, in fact, the combination appeared antagonistic. These results are important as irinotecan
and oxaliplatin are components of the FOLFIRINOX regime.
In our study, the topoisomerase I inhibitor irinotecan did not synergize with nutlin-3a either in the presence and absence of func-
tional TP53 in MIA-PaCa-2 or MIA-PaCa-2 + WT-TP53. In fact, treatment with nutlin-3a appeared to decrease the effects of irinotecan
as an antagonistic response was observed. This lack of increased response to irinotecan could be due to many different factors. Firstly,
the differences between topoisomerase I and topoisomerase II.
Topoisomerase I cleaves single strand DNA and does not need ATP. In contrast, topoisomerase II cleaves double stranded DNA and
requires ATP. The topoisomerase II inhibitors, etoposide, doxorubicin and mitoxantrone may cause more DNA double strand breaks
which synergize with the MDM2 inhibitor-induced delays in repair DSB. Synergy may not be present with the single strand DNA
breaks induced by irinotecan and the nutlin-3a co-treatment. The reasons for antagonism are not clear. It could be a difference in
drug resistance transporters induced by irinotecan in comparison to etoposide, doxorubicin and mitoxantrone. Nutlin-3a could induce
some drug transporters which inhibit the uptake of irinotecan.
Also in our study, nutlin-3a did not appear to increase the response of cells to oxaliplatin. Some studies have observed that in
cells with WT-TP53, synergy was observed between the MDM2 inhibitor MI-219 and oxaliplatin (Azmi et al., 2011). In these studies,
only cells reported to have WT-TP53 were used, moreover quite high concentrations of the MI-219 and oxaliplatin were utilized in
the co-treatment studies, 15μM each. In our studies, only 500nM nutlin-3a was used in the combination experiments. The IC⁠50s for
treatment with oxaliplatin the absence of nutlin-3a in the absence and presence of WT-TP53 were approximately 400nM. These lower
drug doses might explain why we did not observe synergy between oxaliplatin and nutlin-3a treatment. The reasons for antagonism
are not so clear. Some of the drug transporters responsible for oxaliplatin are regulated by TP53. However, it is not so clear how they
are regulated in cells with TP53 GOF mutations.
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Fig. 8. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Metformin and Chloroquine in the Presence and Absence of Nut-
lin-3a. In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of metformin (solid
red squares) and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel B, the two-tailed P value is less
than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with metformin and nutlin-3a and is extremely statistically significant. The experiments in Panels A
and B were performed on the same days. These experiments were repeated 3 times and similar results were observed. In Panel C) MIA-PaCa-2 + pLXSN (Adh.) and in
Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of chloroquine (solid red squares) and a constant dose of 500 nM nutlin-3a
(solid blue triangles) and then MTT analysis was performed after 4 days. In Panel D, the two-tailed P value equals 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.)
cells treated with chloroquine and nutlin-3a and is extremely statistically significant. The experiments in Panels C and D were performed on the same days. These
experiments were repeated 4 times and similar results were observed. (For interpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
Mitoxantrone is a drug that is used to treat multiple sclerosis patients, as well as, certain individuals with hematopoietic and
prostate cancers. Mitoxantrone is a topoisomerase II inhibitor. We observed that introduction of WT-TP53 into MIA-PaCa-2cells
increased their sensitivity to mitoxantrone (Fig. 5, Panel B). Addition of 500 nM nutlin-3a increased the sensitivity of
MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells to mitoxantrone.
Other studies have observed that nutlin-3 can reverse mitoxantrone-resistance in Saos-2 human osteosarcoma cells by inhibiting
breast cancer resistance protein (ABCG2) (Zhang et al., 2011). Likewise, we observed that the topoisomerase II inhibitor mitoxantrone
could also synergize with the MDM2 inhibitor nutlin-3a in suppressing the growth o MIA-PaCa-2 and MIA-PaCa-2+WT-TP53 cells in
a TP53-independent fashion.
Nutlin-3a had some effects on both MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells when they were treated
with the EGFR/HER2 inhibitor ARRY-543 (Fig. 5, Panels C & D). While MIA-PaCa-2 + pLXSN (Adh.) cells were not very sensitive
to ARRY-543 when they were treated with up to 2000 nM, when they were treated with both ARRY-543 and nutlin-3a, they be-
came more sensitive and an IC⁠50 of approximately 800nM was observed. An IC⁠50 of approximately 2,000 nM was observed when
MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with ARRY-543. While the IC⁠50 did not change when these cells were treated with
ARRY-543 and nutlin-3a, the relative level of growth decreased indicating that the nutlin-3a inhibitor was having more effects in the
cells which had WT-TP53. Various miRs regulate EGFR expression (Yin et al., 2013; McCubrey et al., 2018). The effects of combin-
ing EGFR inhibitors and various TP53 activating agents could be an important clinical approach as EGFR is frequently abnormally
expressed in various cancers.
Nutlin-3 treatment sensitized both MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells to the BCL2/BCLXL in-
hibitor ABT-737. BCL2 is a target of various miRs including miR-34a (Ji et al., 2008, 2009). It is conceivable that nutlin-3a treatment
increased TP53 activity which sensitized the cells to the ABT-737 BCL2/BCLXL inhibitor.
Vismodegib is a hedgehog (Hh) pathway inhibitor. Vismodegib inhibits sonic hedgehog (SHH) which is a critical ligand respon-
sible for activation of the pathway. Vismodegib is used in the treatment of certain basal cell carcinomas and has been investigated
in pancreatic cancer patients (Kumar et al., 2015). Treatment with nutlin-3a increased the sensitivity of both MIA-PaCa-2 + pLXSN
and MIA-PaCa-2 +TP53 (WT) cells to vismodegib. miR-602 and miR-608 have been shown to regulate SHH expression (Akhtar et al.,
2015). Combining vismodegib with WT-TP53 reactivating agents could become an effective therapeutic approach for certain cancers.
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Fig. 9. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Berberine and Resveratrol in the Presence and Absence of Nut-
lin-3a. In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of berberine (solid
red squares) and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel A, the two-tailed P value
is less than 0.0001 between MIA-PaCa-2 + pLXSN (Adh.) cells treated with irinotecan and nutlin-3a and is considered extremely statistically significant. In Panel B,
the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with berberine and nutlin-3a and is extremely statistically signifi-
cant. The experiments in Panels A and B were performed on the same days. These experiments were repeated 3 times and similar results were observed. In Panel C)
MIA-PaCa-2 + pLXSN (Adh.) and in Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of resveratrol (solid red squares) and
a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel C, the two-tailed P value is less than 0.0001
between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with resveratrol and nutlin-3a and is extremely statistically significant. In Panel D, the two-tailed P value is less
than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with resveratrol and nutlin-3a and is extremely statistically significant. The experiments in Panels C
and D were performed on the same days. These experiments were repeated 4 times and similar results were observed. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web version of this article.)
In contrast, addition of nutlin-3a to either estrogen or 4HT treated cells had a relatively minor effect on their IC⁠50s (Fig. 7). Al-
though the experiments with estrogen and 4HT did not yield impressive results with MIA-PaCa-2 + pLXSN cells, they do serve as a
control in the sense that they confirm that 500 nM nutlin-3a treatment was not toxic to the cells. Addition of 500 nM nutlin-3a did
increase the sensitivity of MIA-PaCa-2 + WT-TP53 (Adh.) cells to both estrogen and 4HT.
Nutlin-3a had some modest effects on cells treated with metformin and chloroquine. Metformin can have effects on miR-34 and
other miRs (Arunachalam et al., 2016; Bao et al., 2012; Do et al., 2014; Cifarelli et al., 2015; Noren Hanel et al., 2016; Wang et
al., 2018; Wu et al., 2018). Chloroquine can activate TP53 and induce apoptosis in glioblastoma cells (Kim et al., 2010). Addition of
nutlin-3a could enhance the effects of metformin and chloroquine.
The effects of the nutraceuticals such as berberine and curcumin on various human diseases and conditions have been summarized
recently (McCubrey et al., 2017, 2018; Candido et al., 2018). The roles that WT-TP53 or mutant TP53 play in the sensitivities to
nutraceuticals such as berberine, resveratrol and curcumin remain controversial. Some studies have proposed important functions for
WT-TP53 activity in sensitivity to the nutraceuticals (Choi et al., 2009; Katiyar et al., 2009; Chuang et al., 2017). To our knowledge
the effects of nutlin-3a on the sensitivities of PDAC cells to various nutraceuticals in the presence and absence of WT-TP53 have not
been examined.
Other studies have not demonstrated requirements of WT-TP53 activity for the effects of berberine (Wang et al., 2012; Liu et al.,
2013). Also, the various cells and cell lines examined may have different types of TP53 mutations. The differences in the requirement
for WT-TP53 activity may reside in the choice of cells or cell lines which were compared, as well as, the concentrations of berber-
ine used in the studies. Interestingly, some studies have indicated roles for the TP53-regulator MDM2 in the sensitivity of cells to
berberine (Zhang et al., 2010). Berberine may induce TP53 in some cells which leads to induction of miRs important in regulation
of cell growth (Wang et al., 2014). We did observe that introduction of WT-TP53 did increase the sensitivity of the MIA-PaCa-2 cells
to berberine. In contrast, introduction of WT-TP53 made the MIA-PaCa-2 + WT-TP53 cells more resistant to resveratrol. Addition
of nutlin-3a enhanced the effects of berberine in the presence and absence of WT-TP53. Likewise, treatment with 500 nM nutlin-3a
increased the effects of resveratrol.
Some studies have observed the effects of curcumin are TP53-dependent (Jee et al., 1998; Choudhuri et al., 2002, 2005). Other
studies have observed the effects of curcumin are independent of functional WT-TP53 (Watson et al., 2010). We observed that intro
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Fig. 10. Effects of Introduction of WT-TP53 Gene on the Sensitivity of MIA-PaCa-2 Cells to Curcumin and Garcinia Cambogia in the Presence and Absence
of Nutlin-3a. In Panel A) MIA-PaCa-2 + pLXSN (Adh.) and in Panel B) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of curcumin
(solid red squares) and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel A, the two-tailed P
value between MIA-PaCa-2 + pLXSN (Adh.) cells treated with curcumin and nutlin-3a equals 0.0012 which is considered to be very statistically significant. In Panel
B, the two-tailed P value is less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with curcumin and nutlin-3a and is extremely statistically signifi-
cant. The experiments in Panels A and B were performed on the same days. These experiments were repeated 4 times and similar results were observed. In Panel C)
MIA-PaCa-2 + pLXSN (Adh.) and in Panel D) MIA-PaCa-2 + WT-TP53 (Adh.) cells were treated with different concentrations of garcinia cambogia (solid red squares)
and a constant dose of 500 nM nutlin-3a (solid blue triangles) and then MTT analysis was performed after 4 days. In Panel C, the two-tailed P value is less than 0.0001
between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with garcinia cambogia and nutlin-3a and is extremely statistically significant. In Panel D, the two-tailed P value
is less than 0.0001 between MIA-PaCa-2 + WT-TP53 (Adh.) cells treated with garcinia cambogia and nutlin-3a and is extremely statistically significant. The exper-
iments in Panels C and D were performed on the same days. These experiments were repeated 4 times and similar results were observed. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
duction of WT-TP53 resulted in a 1.5-fold increase in sensitivity to curcumin. Upon addition of 500nM nutlin-3a, the IC⁠50s dropped
approximately 1.5–4-fold in MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells, respectively.
MIA-PaCa-2 + pLXSN (Adh.) and MIA-PaCa-2 + WT-TP53 (Adh.) cells had equal sensitivities to garcinia cambogia. Nutlin-3a in-
creased the sensitivities of both cells lines to garcinia cambogia, 10 and 16.7-fold, respectively.
Treatment with nutraceuticals such as berberine, curcumin and resveratrol will result in the induction of various miRs. The induc-
tion of some of the miRs may have beneficial effects on human health (Tili et al., 2010; Bai et al., 2014; Li et al., 2014; Dhar et al.,
2015; Yang et al., 2015; McCubrey et al., 2017; Mirzaei et al., 2018; Otsuka et al., 2018a; Otsuka et al., 2018b). Some of the effects
of co-treatment of cells with nutlin-3a, berberine, curcumin and resveratrol may be enhanced induction of TP53 and the induction of
miR by the nutraceuticals.
Our studies indicate that some PDAC cells will be sensitive to the MDM2 inhibitor nutlin-3a even in the absence of WT-TP53.
Our studies are important as they may expand the types of cancers that could be treated with MDM2 inhibitors. Additional studies to
confirm the “roles” of the TP53 GOF mutation in these cells in the sensitivity to MDM2 inhibitors are important.
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